EA201290956A1 - Вакцина против вич - Google Patents

Вакцина против вич

Info

Publication number
EA201290956A1
EA201290956A1 EA201290956A EA201290956A EA201290956A1 EA 201290956 A1 EA201290956 A1 EA 201290956A1 EA 201290956 A EA201290956 A EA 201290956A EA 201290956 A EA201290956 A EA 201290956A EA 201290956 A1 EA201290956 A1 EA 201290956A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hiv
vaccine against
against hiv
clade
antigens
Prior art date
Application number
EA201290956A
Other languages
English (en)
Inventor
Патрисья Бургиньон
Маргерит Кристин Кутсукос
Кларис Лорен
Лиза Макнэлли
Жераль Эрманн Восс
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA201290956A1 publication Critical patent/EA201290956A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к иммуногенным композициям, включающим антигены ВИЧ-1, и к их применению для терапии и/или профилактики ВИЧ-1. В частности, изобретение относится к применению антигенов ВИЧ-1 из одной клады для профилактики и/или терапии заболевания, ассоциированного с инфекцией ВИЧ-1 из гетерологичной клады ВИЧ-1.
EA201290956A 2010-03-26 2011-03-25 Вакцина против вич EA201290956A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31813010P 2010-03-26 2010-03-26
PCT/EP2011/054654 WO2011117408A1 (en) 2010-03-26 2011-03-25 Hiv vaccine

Publications (1)

Publication Number Publication Date
EA201290956A1 true EA201290956A1 (ru) 2013-04-30

Family

ID=44064896

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290956A EA201290956A1 (ru) 2010-03-26 2011-03-25 Вакцина против вич

Country Status (13)

Country Link
US (1) US20140234399A1 (ru)
EP (1) EP2552480A1 (ru)
JP (1) JP2013523617A (ru)
KR (1) KR20130063493A (ru)
CN (1) CN103221065A (ru)
AU (1) AU2011231574A1 (ru)
CA (1) CA2794558A1 (ru)
EA (1) EA201290956A1 (ru)
IL (1) IL222228A0 (ru)
MX (1) MX2012011189A (ru)
SG (1) SG184188A1 (ru)
WO (1) WO2011117408A1 (ru)
ZA (1) ZA201207030B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2621528A1 (en) * 2010-09-27 2013-08-07 GlaxoSmithKline Biologicals S.A. Vaccine
GB201316463D0 (en) * 2013-09-16 2013-10-30 Giles Clark & Cook Ltd Novel compositions
GB201316464D0 (en) * 2013-09-16 2013-10-30 Giles Clark & Cook Ltd Novel compositions
EP3091990B1 (en) * 2014-01-08 2021-05-12 Mirror Biologics, Inc. Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
WO2015147899A1 (en) * 2014-03-25 2015-10-01 The Government Of The United States Of America As Represented By The Secretary Of The Army Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines
KR102019572B1 (ko) 2014-07-11 2019-09-06 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 톨-유사 수용체의 조정제
WO2016196471A1 (en) 2015-06-02 2016-12-08 Cooper Human Systems Llc Methods and compositions for treatment of hiv infection
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) * 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
KR20200066309A (ko) * 2017-09-08 2020-06-09 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 사포닌을 포함하는 리포솜 제형 및 사용 방법
CN114828884A (zh) * 2019-05-22 2022-07-29 埃利克斯疗法公司 用于疫苗的剂量方案
JP2024504298A (ja) 2021-01-14 2024-01-31 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン及び使用方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
JP2851288B2 (ja) 1987-06-05 1999-01-27 アメリカ合衆国 癌診断および管理における自己分泌運動性因子
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
WO1994000153A1 (en) 1992-06-25 1994-01-06 Smithkline Beecham Biologicals (S.A.) Vaccine composition containing adjuvants
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
UA56132C2 (ru) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
WO2000007631A1 (en) 1998-08-04 2000-02-17 The Henry M. Jackson Foundation Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response
DE602005020608D1 (de) 2004-05-11 2010-05-27 Staat Der Nederlanden Vert Doo NEISSERIA MENINGITIDIS IgtB LOS ALS ADJUVANS
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
CL2008000611A1 (es) * 2007-03-02 2008-09-05 Glaxosmithkline Biolog Sa Procedimiento para fomentar respuesta inmunitaria frente a un patogeno que comprende administrar i) uno o mas polipeptidos inmunogenicos derivados del patogeno, ii) uno o mas vectores adenoviricos que comprenden uno o mas polinucleotidos que codifica
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions

Also Published As

Publication number Publication date
CN103221065A (zh) 2013-07-24
EP2552480A1 (en) 2013-02-06
WO2011117408A1 (en) 2011-09-29
JP2013523617A (ja) 2013-06-17
MX2012011189A (es) 2013-02-07
CA2794558A1 (en) 2011-09-29
IL222228A0 (en) 2012-12-31
US20140234399A1 (en) 2014-08-21
SG184188A1 (en) 2012-10-30
AU2011231574A1 (en) 2012-10-11
KR20130063493A (ko) 2013-06-14
ZA201207030B (en) 2013-05-29

Similar Documents

Publication Publication Date Title
EA201290956A1 (ru) Вакцина против вич
CY1124043T1 (el) Εξουδετερωτικα αντισωματα του ανθρωπινου ιου της ανοσοανεπαρκειας και μεθοδοι χρησης αυτων
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
CY1117673T1 (el) Ανασυνδυασμενα αντιγονα rsv
MD20200093A2 (ru) Полициклические соединения карбамоилпиридона и их фармацевтическое применение
PH12015501156A1 (en) Pharmaceutical compositions
MY168959A (en) Vaccine compositions for the prevention of dengue virus infection
PH12014502875A1 (en) Vaccine compositions for prevention against dengue virus infection
EA201391515A1 (ru) Инактивированная вакцина вируса денге
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
IN2014KN02740A (ru)
MX343505B (es) Metodos y composiciones para inhibir la transmision del vih.
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
EA201790495A1 (ru) Фармацевтические композиции длительного действия
WO2012047267A3 (en) Polyvalent immunogen
UA118542C2 (uk) Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
WO2016100615A3 (en) Methods and composition for neutralization of influenza
WO2015086738A3 (en) Hiv vaccine
ZA202104746B (en) Novel trypanosomal vaccine
EA201390452A1 (ru) Вакцина
EA201300134A1 (ru) Фармацевтическая композиция и способ лечения и профилактики заболеваний, вызванных или связанных с вич